The cientificWorldJOURNAL Research Article Development and Validation of an RP-HPLCMethod for CB13 Evaluation in Several PLGANanoparticle Systems

Copyright © 2012 J. Álvarez-Fuentes et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. A simple, fast, and reversed-phase high-performance liquid chromatographic (RP-HPLC) method has been developed and valida-ted for determining of a cannabinoid derivate, which displays potent antihyperalgesic activity, 1-naphthalenyl[4-(pentyloxy)-1-naphthalenyl]methanone (CB13) into PLGA nanoparticles. Separation was achieved in a C18 column using a mobile phase con-sisting of two solvents: solvent A, consisting of acetonitrile: water: acetic acid (75: 23.7: 1.3 v/v), and solvent B, consisting of ace-tonitrile. An isocratic method (70: 30 v/v), with a flow rate of 1.000mL/min, and a diode array detector were used. The developed method was precise, accurate, and linear over the concentration range of analysis with a limit of detection and a limit of quan-tification of 0.5 and 1.25 µg/mL, respectively. The developed method was applied to the analysis of CB13 in nanoparticles samples obtained by three different procedures (SEV, FF, and NPP) in terms of encapsulation efficiency and drug release. Nanoparticles size and size distribution were also evaluated founding that NPP method presented the most lowest particle sizes with narrow-size distribution (≈320 nm) and slightly negative zeta potential ( ≈ −25mV) which presumes a suitable procedure for the synthesis of PLGA-CB13 nanoparticles for oral administration. 1